Tina Ticinovic Kurir

Oct 1, 2024 | radcliffecardiology.com | Sanjiv Shah |Erin D. Michos |Alison Bailey |Tina Ticinovic Kurir

Video Published: Views: 2 Likes: 0 Average (ratings) HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892). EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.

Apr 15, 2023 | radcliffecardiology.com | Josip Katic |Josip A. Borovac |Marko Kumric |Tina Ticinovic Kurir

Dr. Josip A. Borovac is a Research Associate at the Department of Pathophysiology, University of Split School of Medicine, and a Cardiology Fellow at the Clinic for Heart and Vasular Diseases, University Hospital of Split, Croatia.